<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02698657</url>
  </required_header>
  <id_info>
    <org_study_id>5094-CL-0102</org_study_id>
    <secondary_id>2015-004562-28</secondary_id>
    <nct_id>NCT02698657</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate</brief_title>
  <official_title>A Phase 1, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Global Development, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of
      multiple ascending intravenous doses of ASP5094 in male and female subjects with rheumatoid
      arthritis (RA) on methotrexate (MTX).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2016</start_date>
  <completion_date type="Actual">September 7, 2017</completion_date>
  <primary_completion_date type="Actual">September 7, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by Adverse Events (AEs)</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with abnormal laboratory values and/or adverse events related to treatment</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by 12-lead electrocardiogram (ECG)</measure>
    <time_frame>Up to 5 months</time_frame>
    <description>The overall conclusion will be recorded as normal, abnormal not clinically significant, or abnormal clinically significant.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with physical examination abnormalities and/or adverse events related to treatment</measure>
    <time_frame>Up to 5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by antiASP5094 antibody formation</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by total lymphocyte counts</measure>
    <time_frame>Up to 5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by peripheral lymphocyte subsets</measure>
    <time_frame>Up to 5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP5094 in plasma: AUCtau</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Area under the concentration-time curve from the time of dosing to the start of the next dosing interval (AUCtau)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP5094 in plasma: tmax</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Time of maximum concentration (tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP5094 in plasma: Cmax</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Maximum concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP5094 in plasma: Ctrough</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Concentration immediately prior to dosing at multiple dosing (Ctrough)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP5094 in plasma: Rac(AUC)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Accumulation ratio of AUC (Rac(AUC))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ASP5094 in plasma: Rac(Cmax)</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Accumulation ratio of Cmax (Rac(Cmax))</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by vital sign measurement: oral temperature</measure>
    <time_frame>Up to 5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by vital sign measurement: pulse</measure>
    <time_frame>Up to 5 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by vital sign measurement: supine blood pressure</measure>
    <time_frame>Up to 5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ASP5094 in plasma: t1/2</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Terminal elimination half-life (t1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ASP5094 in plasma: Vz</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Volume of distribution during terminal elimination phase after intravenous dosing (Vz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ASP5094 in plasma: CL</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Total systemic clearance after intravenous dosing (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ASP5094 in plasma: Fluctuation (%)</measure>
    <time_frame>Up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Rheumatoid Arthritis (RA)</condition>
  <arm_group>
    <arm_group_label>ASP5094 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three sequential cohorts will receive increasing intravenous doses of ASP5094. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Dose Escalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Three sequential cohorts will receive increasing intravenous doses of Placebo. After all subjects in a cohort have completed study procedures the overall safety and tolerability of the dose will be determined after evaluation of the safety data. If there are no events which meet the stopping criteria, the next sequential cohort will begin enrollment while the current subjects continue through the third dose and the remainder of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP5094</intervention_name>
    <description>Intravenous (IV)</description>
    <arm_group_label>ASP5094 Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous (IV)</description>
    <arm_group_label>Placebo Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a body mass index (BMI) of ≤ 35 kg/m2, inclusive, and must weigh at least
             50 kg at screening.

          -  Subject has absolute neutrophil count within normal limits at screening. The
             assessment may be repeated once during screening.

          -  Subject has RA that was diagnosed according to the 1987 revised criteria of the
             American College of Rheumatology (ACR) ≥ 6 months prior to screening.

          -  Subject meets the ACR 1991 revised criteria for Global Functional Status in RA, Class
             I, II or III at screening.

          -  Subject MUST be on concomitant MTX:

               -  for ≥ 3 months prior to day 1, and

               -  at a stable dose (10 25 mg/week) for ≥ 28 days prior to day 1 and throughout the
                  study.

          -  Subject's other medications taken for the treatment of RA at the time of screening
             must meet the noted stability requirements and remain on a stable regimen, as follows:

               -  Nonsteroidal antiinflammatory drugs (NSAIDs), selective cyclooxygenase-2 (COX- 2)
                  inhibitors, oral corticosteroids (≤ 10 mg of prednisone, or equivalent, daily) or
                  low dose opioids (≤ 30 mg of oral morphine, or equivalent, daily) must be stable
                  for ≥ 28 days prior to screening,

               -  Hydroxychloroquine (Plaquenil®) and sulfasalazine (e.g., Azulfidine®) must have
                  started ≥ 2 months, and be stable for ≥ 28 days, prior to day 1.

          -  Female subject must be either:

               -  Of nonchildbearing potential: postmenopausal (defined as at least 1 year without
                  any menses) prior to screening, or documented surgically sterile

               -  Or, if of childbearing potential, Agree not to try to become pregnant during the
                  study and for 60 days after the final study drug administration; must have a
                  negative urine pregnancy test at screening and day 1, And, if heterosexually
                  active, agree to consistently use 2 forms of highly effective birth control† (at
                  least 1 of which must be a barrier method) starting at screening and throughout
                  the study period and for 60 days after the final study drug administration.

          -  Female subject must agree not to breastfeed starting at screening and throughout the
             study period, and for 60 days.

          -  Female subject must not donate ova starting at screening and throughout the study
             period, and for 60 days after the final study drug administration.

          -  Male subject and his female spouse/partner who is of childbearing potential must be
             using highly effective forms of contraception consisting of 2 forms of birth control†
             (1 of which must be a barrier method) starting at screening and continue throughout
             the study period and for 60 days after the final study drug administration.

          -  Male subject must not donate sperm starting at screening and throughout the study
             period, and for 60 days after the final study drug administration

          -  Subject agrees not to participate in another interventional study while participating
             in the present study, defined as signing the informed consent form until completion of
             the last study visit.

        Exclusion Criteria:

          -  Subject has an ongoing clinically significant systemic disease such as uncompensated
             heart failure, uncontrolled diabetes mellitus, severe hepatic failure, severe
             pulmonary disease or inflammatory bowel disease.

          -  Subject has a history of any malignancy in the past 5 years, except for
             adequately-treated, nonmelanoma skin cancer and adequately-treated in-situ cervical
             cancer.

          -  Subject has a history of severe allergic or anaphylactic reactions to drugs.

          -  Subject has a history of consuming more than 14 units of alcoholic beverages per week
             or has a history of alcoholism or drug/chemical/ substance abuse within past 6 months
             prior to screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of
             spirits).

          -  Subject has an ongoing infection or has had an infection requiring intravenous
             antibiotics within 1 month prior to day 1.

          -  Subject has a known history of a positive test for human immunodeficiency virus (HIV)
             antibody.

          -  Subject has a past history of serious opportunistic infection.

          -  Subject has a positive QuantiFERON-TB Gold test within 90 days of, or at screening,
             and has not completed an adequate course of antimicrobial therapy per Centers for
             Disease Control or local guidelines.

          -  Subject's laboratory test results at screening or prior to study drug dosing on day 1:

               -  Outside the normal limits and considered by the investigator to be clinically
                  significant with regard to the remaining per-protocol laboratory tests, and/or

               -  Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) are &gt; 2
                  times the upper limit of normal.

          -  Subject received any live or live-attenuated vaccine within 30 days prior to day 1.

          -  Subject received any of the following:

               -  Oral or injectable gold, azathioprine, penicillamine, cyclosporine, tacrolimus or
                  tofacitinib (Xeljanz®) within 30 days prior to day 1.

               -  Anakinra (Kineret®), etanercept (Enbrel®), adalimumab (Humira®), tocilizumab
                  (Actemra®), infliximab (Remicade®), or golimumab (Simponi®) within 60 days prior
                  to day 1.

               -  Leflunomide (Arava®) within 60 days prior to day 1, unless the subject has
                  undergone cholestyramine washout at least 30 days prior to day 1.

               -  Certolizumab (Cimzia®) and abatacept (Orencia®) within 90 days prior to day 1.

               -  Rituximab (Rituxan®) or any other antiCD20 antibody, and cyclophosphamide within
                  180 days prior to day 1.

               -  Treatment with any other conventional disease modifying antirheumatic drugs
                  (DMARDs), or treatment with any other biologics not previously noted within 28
                  days or 5 half-lives, whichever is longer, prior to day 1.

          -  Subject has participated in a previous clinical study with treatment with ASP5094 or
             has participated in another dose cohort of the current trial.

          -  Subject has previously received an experimental agent within 28 days or 5 half-lives,
             whichever is longer, prior to day 1.

          -  Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or more,
             or received a transfusion of any blood or blood products within 60 days or donated
             plasma within 7 days prior to day 1.

          -  Subject had surgery or has a planned elective surgery (including oral surgery) within
             1 month prior to screening and 3 months after last study drug administration.

          -  Subject has a wound that is currently healing.

          -  Subject has any other condition, which in the opinion of the investigator, precludes
             the subject's participation in the trial.

          -  Subject is an employee of the Astellas group or vendors involved in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senior Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site US10002</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10008</name>
      <address>
        <city>DeBary</city>
        <state>Florida</state>
        <zip>32713-1818</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10004</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10009</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10003</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10010</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site US10001</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48009</name>
      <address>
        <city>Elblag</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48011</name>
      <address>
        <city>Krakow</city>
        <zip>31-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48006</name>
      <address>
        <city>Lodz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48007</name>
      <address>
        <city>Stalowa Wola</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48003</name>
      <address>
        <city>Warszawa</city>
        <zip>00-660</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site PL48008</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-556</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis (RA)</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>ASP5094</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

